Gamida Cell Ltd GMDA:NASDAQ

Last Price$1.77NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change+0.04(2.31%)
Bid (Size)$1.67 (5)
Ask (Size)$1.78 (3)
Day Low / High$1.67 - 1.81
Volume296.0 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/30/2022


Gamida Cell Ltd ( NASDAQ )

Price: $1.77
Change: +0.04 (2.31%)
Volume: 296.0 K
4:00PM ET 6/30/2022

Checkpoint Therapeutics Inc ( NASDAQ )

Price: $1.03
Change: -0.03 (2.83%)
Volume: 251.1 K
4:00PM ET 6/30/2022

Assembly Biosciences Inc ( NASDAQ )

Price: $2.10
Change: -0.03 (1.41%)
Volume: 234.7 K
4:00PM ET 6/30/2022

OncoCyte Corp ( NASDAQ )

Price: $0.90
Change: +0.04 (4.62%)
Volume: 638.6 K
4:00PM ET 6/30/2022

Dare Bioscience Inc ( NASDAQ )

Price: $1.23
Change: -0.02 (1.60%)
Volume: 2.7 M
4:00PM ET 6/30/2022

Read more news Recent News

Gamida Cell Completes Rolling Biologics License Application Submission With FDA for Blood Cancer Drug
7:56AM ET 6/02/2022 MT Newswires

Gamida Cell (GMDA) said Thursday it has completed the submission of a rolling biologics license application with the US Food and Drug Administration for...

Gamida Cell Screens Patients for Enrollment in Phase 1/2 Study of Lymphoma Therapy Candidate
7:50AM ET 6/01/2022 MT Newswires

Gamida Cell (GMDA) said Wednesday it has activated the initial clinical sites to screen and enroll patients in a Phase 1/2 study of its GDA-201 cell...

Sector Update: Health Care Stocks Remain in Decline Late Tuesday
2:37PM ET 4/26/2022 MT Newswires

Health care stocks remained on the decline in late Tuesday afternoon trading, with the NYSE Health Care Index down 1.3% and the Health Care Select Sector...

Sector Update: Health Care Stocks Decline Midday Tuesday
12:42PM ET 4/26/2022 MT Newswires

Health care stocks were on the decline in early Tuesday afternoon trading, with the NYSE Health Care Index down 1% and the Health Care Select Sector SPDR...

Company Profile

Business DescriptionGamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA. View company web site for more details
Address116 Huntington Avenue
Boston, Massachusetts 02116
Number of Employees73
Recent SEC Filing06/22/2022DEF 14A
Chief Executive Officer & DirectorJulian Adams
Chief Operating & Commercial OfficerMichele I. Korfin
Chief Financial OfficerShai Lankry
Chief Medical & Scientific OfficerRonit Simantov

Company Highlights

Price Open$1.70
Previous Close$1.73
52 Week Range$1.67 - 6.84
Market Capitalization$106.2 M
Shares Outstanding60.0 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.03
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-168.06%

Analyst Ratings as of 06/15/2022

Consensus RecommendationConsensus Icon
Powered by Factset